Search This Blog

Thursday, September 29, 2022

C4 Receives Study May Proceed Letter from FDA for Cancer Phase 1/2

 Phase 1/2 Clinical Trial Will Study CFT1946 in BRAF-V600 Mutant Solid Cancers Including Lung, Colorectal and Melanoma; Trial Initiation Expected by Year End 2022

https://finance.yahoo.com/news/c4-therapeutics-receives-study-may-110000094.html

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)